[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465574":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":10,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Otsuka Pharmaceutical Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Drug",null,"Ajovy syringe for SC injection 225 mg.",[13],"Drug: Fremanezumab 225 Mg\u002F1.5 mL Subcutaneous Solution",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Fremanezumab 225 Mg\u002F1.5 mL Subcutaneous Solution","The usual adult dose is 225 mg of fremanezumab (genetical recombination) administered subcutaneously as a single dose once every 4 weeks or 675 mg administered subcutaneously as a single dose once every 12 weeks.",[9],[21],{"name":22,"affiliation":5,"role":23},"Yasuhiko Fukuta, PhD","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd","CONTACT","+81-6-6943-7722","komaniwa.satoshi@otsuka.jp",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Pharmacovigilance Department","RECRUITING","Osaka","540-0021","Japan",{"type":38,"coordinates":39},"Point",[40,41],135.50107,34.69379,{"lat":41,"lon":40},[44],{"name":45,"role":27,"phone":10,"phoneExt":10,"email":10},"Satoshi Komaniwa, PhD",{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100465574",false,"NCT05342493","Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use","AJOVY Subcutaneous Injection Long-term Specified Use-results Survey","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n* patients with a known hypersensitivity to components of AJOVY","ALL","18 Years",{"count":57,"type":58},1000,"ESTIMATED","OBSERVATIONAL","To evaluate the long-term safety of AJOVY in patients under actual use conditions and to specifically evaluate cardiovascular events. In addition, information on efficacy will be collected.",[62],"Migraine Disorders","2026-06-17",{"date":65,"type":66},"2026-06-22","ACTUAL",{"date":68,"type":66},"2022-04-20",{"date":70,"type":58},"2029-06-22",{"name":5,"class":6},1]